Interní Med. 2015; 17(5): 233-238

News in cardiovascular prevention: from guidelines to novel treatment options

doc.MUDr.Michal Vrablík, Ph.D.
Centrum preventivní kardiologie, 3. interní klinika, 1. LF UK a VFN, Praha

Cardiovascular (CV) prevention remains a top priority not only in our country. Despite a significant decrease of CV mortality the Czech

Republic remains a country with a high CV mortality rate. There are more reasons, low attainment of treatment targets being the most

important. Options for reduction of atherothrombotic complication risk have widened over recent years. Brand new approaches in the

treatment of dyslipidemia including PCSK9 inhibition or therapies utilizing anti-sense technologies rapidly have emerged. We have

already learned about their lipid-modifying efficacy but also the first evidence regarding their impact on the risk of vascular events

Keywords: prevention, dyslipidemia, statins, ezetimibe, PCSK9 inhibitors

Published: December 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vrablík M. News in cardiovascular prevention: from guidelines to novel treatment options. Interní Med. 2015;17(5):233-238.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Zdravotnická statistika. Zemřelí 2013. Dostupné na www.uzis.cz.
    2. Townsend N, Nichols M, Scarborough P, et al. Cardiovascular disease in Europe-epidemiological update 2015. Eur Heart J 2015. Go to original source... Go to PubMed...
    3. Kotseva K, Wood D, De Backer G, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009; 373: 929-940. Go to original source... Go to PubMed...
    4. Mayer O, Bruthans J, EUROASPIRE study group. Nakolik jsme schopni dosáhnout současně platných cílových hodnot LDL-cholesterolu v sekundární prevenci ischemické choroby srdeční? Vnitr Lek 2015; 61: 439-446. Go to PubMed...
    5. Soška V, Vaverková H, Vrablík M, et al. Stanovisko výboru ČSAT k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2011. DMEV 2013; 16: 24-29.
    6. Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 2011; 217(1): 3-46. Go to original source... Go to PubMed...
    7. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013, doi: 10.1161/01.cir.0000437741.48606.98. Go to original source... Go to PubMed...
    8. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013, doi: 10.1161/01.cir.0000437738.63853.7a. Go to original source... Go to PubMed...
    9. Štulc T, Šnejdrlová M, Češka R. Prevence kardiovaskulárních onemocnění v běžné klinické praxi: lze dosáhnout zlepšení? Vnitr Lek. 2014; 60(11): 931-936. Go to PubMed...
    10. UK Prospective 9. Diabetes Study (UKPDS)Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
    11. Wilcox R, Kupfer S, Erdmann E; PROactive Study investigators. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J. 2008; 155(4): 712-717. Go to original source... Go to PubMed...
    12. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369(14): 1317-1326. Go to original source... Go to PubMed...
    13. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Sep 17. [Epub ahead of print]. Go to original source... Go to PubMed...
    14. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. The New England journal of medicine. 2015; 372(25): 2387-2397. Go to original source... Go to PubMed...
    15. Soška V. Komentář k novým analýzám výsledků studie IMPROVE-IT. Hypertenze a KV prevence 2015, v tisku.
    16. Sahebkar A, Watts GF. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther 2013; 35: 1082-1098. Go to original source... Go to PubMed...
    17. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009; 50(suppl): S172-S177. Go to original source... Go to PubMed...
    18. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of monoclonal antibody to PCSK9 on plasma LDL cholesterol. N Engl J Med 2012; 366: 1108-1118. Go to original source... Go to PubMed...
    19. Stein EA, Wasserman SM, Dias C, et al. AMG-145. Drugs of the Future 2013; 38: 451-459. Go to original source...
    20. Reichert JM. Antibodies to watch in 2014. MAbs 2014; 6: 5-14. Go to original source... Go to PubMed...
    21. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-1509. Go to original source... Go to PubMed...
    22. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.